Nomura released a research report that maintained Wuxi Biologics's (02269) "buy" rating and expected revenue to grow 62 per cent and net profit 37 per cent in the first half of this year compared with the same period last year, Zhitong Financial APP learned. At the same time, the revenue forecast for fiscal year 2022Unix 23 will be increased by 3% by 4%, and the profit forecast by 10% by 6%, to reflect stronger growth momentum, with the target price rising from HK $95.75 to HK $97.78.

According to the report, the strategic cooperation between the company and AstraZeneca PLC (AZN.US) on the localized production of COVID-19 's preventive drug "Enshi" is another cooperation after COVID-19 's vaccine cooperation, reflecting the deeper trust between the two sides.